NCT00257478已完成2 期
A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 9
研究概览
简要总结
A study for the treatment of hormone refractory prostate cancer (HRPC) in patients previously treated with chemotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed prostate cancer.
- •Prior chemotherapy regimen for prostate cancer
排除标准
- •History of other malignancy in the last 5 years
- •Major surgery within the past 21 days
研究者
研究点 (9)
Loading locations...
相似试验
已完成
1 期
Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate CancerNeoplasm MetastasisProstate CancerNCT00323882Bristol-Myers Squibb75
终止
2 期
A Phase II Study of Degarelix in the Management of Non-Metastatic Hormone-Refractory Prostate CancerProstatic NeoplasmsNCT01545882Ottawa Hospital Research Institute5
Unknown
不适用
Circulating Tumor Cells and Survival in Hormone Refractory Prostate Cancer (HRPC) Patients Receiving ChemotherapyHormone Refractory Prostate CancerProstate CancerNCT00133900Immunicon276
Unknown
2 期
Phase II Study of RAD001 in a Neoadjuvant Setting in Men With Intermediate or High Risk Prostate CancerProstate CancerNCT00657982Sheba Medical Center15
已完成
不适用
Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH AgonistsProstate CancerNCT01366053CMX Research125